Abstract
Antiplatelet therapy is used to reduce the risk of ischemic events in patients with cardiovascular disease. The balance of benefits and risks of antiplatelet drugs in coronary artery disease has been evaluated in large-scale randomised trials, however the absolute benefit for an individual patient and a specific platelet-active drug need further evaluation. Several well-conducted studies have demonstrated a substantial inter-individual variability in the platelet responsiveness to drugs. The historical “gold standard” test of platelet function (optical aggregation) has well established limitations for measuring the effect of antiplatelet drugs. Other new tests developed (i.e. PFA-100®, VerifyNow®) may overcome some of these limitations but they do not correlate well with each other. Despite these unresolved methodological questions, several recent clinical studies, but not all, suggest a significant correlation between antiplatelet resistance status and serious vascular events. In these conditions, laboratory monitoring for antiplatelet therapies raises several questions: (i) the necessity for a consensus on the definition of resistance and on the best test for evaluation of the condition, (ii) the demonstration that biological resistance has clinical significance, and (iii) the clinical impact of adapting the antiplatelet therapy. Therefore, it is not currently appropriate to test patients or to change therapy on the basis of such tests, other than in prospective and adequately powered clinical trials.
Keywords: Aspirin, clopidogrel, coronary artery disease, platelet aggregation inhibitors, platelet function
Current Vascular Pharmacology
Title: Monitoring of the Antiplatelet Drugs Effect in Patients with Coronary Artery Disease: What is the Real Clinical Impact?
Volume: 5 Issue: 4
Author(s): Luc Christiaens and Laurent Macchi
Affiliation:
Keywords: Aspirin, clopidogrel, coronary artery disease, platelet aggregation inhibitors, platelet function
Abstract: Antiplatelet therapy is used to reduce the risk of ischemic events in patients with cardiovascular disease. The balance of benefits and risks of antiplatelet drugs in coronary artery disease has been evaluated in large-scale randomised trials, however the absolute benefit for an individual patient and a specific platelet-active drug need further evaluation. Several well-conducted studies have demonstrated a substantial inter-individual variability in the platelet responsiveness to drugs. The historical “gold standard” test of platelet function (optical aggregation) has well established limitations for measuring the effect of antiplatelet drugs. Other new tests developed (i.e. PFA-100®, VerifyNow®) may overcome some of these limitations but they do not correlate well with each other. Despite these unresolved methodological questions, several recent clinical studies, but not all, suggest a significant correlation between antiplatelet resistance status and serious vascular events. In these conditions, laboratory monitoring for antiplatelet therapies raises several questions: (i) the necessity for a consensus on the definition of resistance and on the best test for evaluation of the condition, (ii) the demonstration that biological resistance has clinical significance, and (iii) the clinical impact of adapting the antiplatelet therapy. Therefore, it is not currently appropriate to test patients or to change therapy on the basis of such tests, other than in prospective and adequately powered clinical trials.
Export Options
About this article
Cite this article as:
Christiaens Luc and Macchi Laurent, Monitoring of the Antiplatelet Drugs Effect in Patients with Coronary Artery Disease: What is the Real Clinical Impact?, Current Vascular Pharmacology 2007; 5 (4) . https://dx.doi.org/10.2174/157016107782023361
DOI https://dx.doi.org/10.2174/157016107782023361 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthetic Routes to Spirocyclic Pyridazines, Partially-Saturated Pyridazines and Their Condensed Derivatives
Current Organic Chemistry Expeditious and Green Synthesis of 2,3-Dihydroquinazolin-4(1H)-ones Catalyzed by Nano-MgO
Letters in Organic Chemistry A Review on Mechanisms of Anti Tumor Activity of Chalcones
Anti-Cancer Agents in Medicinal Chemistry Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Written Consent to Use the Drug in Children: The Problem of Off-Label Drugs
Current Pharmaceutical Design Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Sarcolemmal K<sub>ATP</sub> Channel Modulators and Cardiac Arrhythmias
Current Medicinal Chemistry Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis
Current Drug Targets Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews Family B G Protein-coupled Receptors and their Ligands: From Structure to Function
Current Medicinal Chemistry Acyl Thiourea Derivatives Containing Pyrazole Ring Selective Targeting of Human Aurora Kinases in Breast and Bone Cancer
Letters in Drug Design & Discovery Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Snake Venom Proteins Isolated from Tunisian Vipers: Pharmacological and Therapeutic Overview
Venoms and Toxins Nicotinamide Phosphoribosyltransferase as a Target in Inflammation- Related Disorders
Current Topics in Medicinal Chemistry Q Fever Endocarditis
Infectious Disorders - Drug Targets Protein Kinases and Associated Pathways in Pluripotent State and Lineage Differentiation
Current Stem Cell Research & Therapy An Insight Into Mitochondrial Dysfunction and its Implications in Neurological Diseases
Current Drug Targets CD8<sup>+</sup> T Cell Responses to Plasmodium and Intracellular Parasites
Current Immunology Reviews (Discontinued) Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design